Oxana Beskrovnaya, Chief Scientific Officer at Dyne Therapeutics, Inc. (DYN), sold 175,558 shares at $18.34 ($3.3M) on 2024-01-03, disclosed to the SEC on 2024-01-04.
Scheduled sale ($3.3M) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $18.34 | 15,382 | $282K | 8.7% |
| 2 | $18.34 | 15,382 | $282K | 8.7% |
| 3 | $19.05 | 24,583 | $468K | 14.4% |
| 4 | $19.05 | 24,583 | $468K | 14.4% |
| 5 | $20.50 | 5,361 | $110K | 3.4% |
| 6 | $20.50 | 5,361 |
| $110K |
| 3.4% |
| 7 | $18.13 | 42,453 | $770K | 23.6% |
| 8 | $18.13 | 42,453 | $770K | 23.6% |
| Total | $18.57 avg | 175,558 | $3.3M | 100% |
| Filing → |
| DYN | SELL | 2025-02-25 | $36K | — | Filing → |
| DYN | SELL | 2024-12-11 | $131K | — | Filing → |
| DYN | SELL | 2024-11-18 | $161K | — | Filing → |